These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33077514)

  • 1. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
    Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.
    Loree JM; Titmuss E; Topham JT; Kennecke HF; Feilotter H; Virk S; Lee YS; Banks K; Quinn K; Karsan A; Renouf DJ; Jonker DJ; Tu D; O'Callaghan CJ; Chen EX
    Clin Cancer Res; 2024 Aug; 30(15):3189-3199. PubMed ID: 38727700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
    Friedlaender A; Nouspikel T; Christinat Y; Ho L; McKee T; Addeo A
    Front Oncol; 2020; 10():142. PubMed ID: 32117779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
    Sun LY; Cen WJ; Tang WT; Long YK; Yang XH; Ji XM; Yang JJ; Zhang RJ; Wang F; Shao JY; Du ZM
    Cancer Med; 2021 Oct; 10(19):6610-6617. PubMed ID: 34469045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
    Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
    Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
    Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target.
    Xu M; Ma X; Wang Y; Yu Z; Zheng X; Dai H; Xue C
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):313. PubMed ID: 38900244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
    Anagnostou V; Niknafs N; Marrone K; Bruhm DC; White JR; Naidoo J; Hummelink K; Monkhorst K; Lalezari F; Lanis M; Rosner S; Reuss JE; Smith KN; Adleff V; Rodgers K; Belcaid Z; Rhymee L; Levy B; Feliciano J; Hann CL; Ettinger DS; Georgiades C; Verde F; Illei P; Li QK; Baras AS; Gabrielson E; Brock MV; Karchin R; Pardoll DM; Baylin SB; Brahmer JR; Scharpf RB; Forde PM; Velculescu VE
    Nat Cancer; 2020 Jan; 1(1):99-111. PubMed ID: 32984843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
    Lu M; Wu KH; Trudeau S; Jiang M; Zhao J; Fan E
    Sci Rep; 2020 Nov; 10(1):20575. PubMed ID: 33239757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Pinato DJ; Urus H; Newsom-Davis T; Du Parcq P; Belessiotis K; Mapara L; Gupta N; Power D; Weir J; Wong CN; Ratnakumaran RP; Dominy K; Khorashad J; Bower M
    J Immunother; 2020; 43(2):53-56. PubMed ID: 31567705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making.
    Sun D; Xu M; Pan C; Tang H; Wang P; Wu D; Luo H
    Front Oncol; 2022; 12():972972. PubMed ID: 36425562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
    Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
    Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.